TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Traders acquired 13,983 call options on the stock. This represents an increase of approximately 88% compared to the average daily volume of 7,433 call options.

Insider Buying and Selling at TG Therapeutics

In related news, Director Laurence N. Charney sold 22,000 shares of the business's stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total value of $351,340.00. Following the completion of the transaction, the director now owns 215,229 shares in the company, valued at approximately $3,437,207.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 9.20% of the company's stock.

Institutional Investors Weigh In On TG Therapeutics

Several large investors have recently made changes to their positions in the stock. Principal Financial Group Inc. lifted its position in TG Therapeutics by 3.9% in the 1st quarter. Principal Financial Group Inc. now owns 35,374 shares of the biopharmaceutical company's stock valued at $538,000 after acquiring an additional 1,322 shares in the last quarter. Wealth Effects LLC lifted its holdings in shares of TG Therapeutics by 17.9% in the first quarter. Wealth Effects LLC now owns 16,500 shares of the biopharmaceutical company's stock valued at $251,000 after purchasing an additional 2,500 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in shares of TG Therapeutics by 4.4% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 107,420 shares of the biopharmaceutical company's stock worth $1,634,000 after buying an additional 4,548 shares during the period. Hennion & Walsh Asset Management Inc. grew its holdings in shares of TG Therapeutics by 16.9% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 184,815 shares of the biopharmaceutical company's stock worth $2,811,000 after buying an additional 26,761 shares in the last quarter. Finally, Los Angeles Capital Management LLC raised its position in TG Therapeutics by 55.8% in the 1st quarter. Los Angeles Capital Management LLC now owns 76,616 shares of the biopharmaceutical company's stock valued at $1,165,000 after buying an additional 27,437 shares during the last quarter. Institutional investors own 58.58% of the company's stock.

Wall Street Analysts Forecast Growth

TGTX has been the topic of a number of research reports. HC Wainwright restated a "buy" rating and set a $45.00 target price on shares of TG Therapeutics in a research report on Thursday, April 18th. StockNews.com cut shares of TG Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, February 24th. JPMorgan Chase & Co. reissued an "overweight" rating and issued a $25.00 price target on shares of TG Therapeutics in a research note on Thursday, April 18th. LADENBURG THALM/SH SH reaffirmed a "buy" rating and set a $39.00 price objective on shares of TG Therapeutics in a research note on Thursday, April 18th. Finally, B. Riley increased their target price on TG Therapeutics from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Monday, February 5th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, TG Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $29.00.

TG Therapeutics Trading Up 16.3 %

TGTX stock traded up $2.22 during midday trading on Wednesday, hitting $15.88. 18,586,466 shares of the company's stock were exchanged, compared to its average volume of 4,285,174. TG Therapeutics has a one year low of $6.46 and a one year high of $35.67. The company has a debt-to-equity ratio of 0.62, a quick ratio of 5.18 and a current ratio of 5.92. The company has a market cap of $2.45 billion, a PE ratio of 769.38 and a beta of 2.30. The stock's fifty day moving average price is $15.07 and its 200-day moving average price is $14.32.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.03. TG Therapeutics had a return on equity of 12.89% and a net margin of 5.42%. The business had revenue of $43.97 million for the quarter, compared to analysts' expectations of $40.06 million. During the same quarter in the previous year, the business posted ($0.39) EPS. Research analysts predict that TG Therapeutics will post -0.11 earnings per share for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.